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The pioneers of tumor immunology and cancer immunotherapy, including the late William B. Coley and Lloyd J. Old,
have championed the potential for immunotherapy for over a century. Finally, advances in our understanding of the
fundamentals of tumor immunology are translating into clinical success, with recent US Food and Drug Administration
approval of several immunotherapies that improve clinical outcomes across prostate cancer, metastatic melanoma,
non-small cell lung cancer and lymphocytic leukemia. In tandem with these clinical successes, new technologies such
as high-throughput DNA/RNA sequencing, genetic engineering, and streamlined ex vivo cell culturing have paved the
way for the next generation of immunotherapies and provided new tools for investigating potential biomarkers of
response to existing therapies. During the November 2014 Annual Meeting of the Society of the Immunotherapy of
Cancer, leaders in tumor immunology and cancer immunotherapy convened at the second annual SITC Primer to
review both current knowledge and future directions in the field. Here, we will review the key discussions across a
variety of topics, including innate immunity, adaptive immunity, dendritic cells, adoptive T cell therapy, anti-tumor
antibodies, cancer vaccines, immune checkpoint blockade, challenges to immunotherapy, monitoring immune
responses, and immunotherapy clinical trial design.
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Clinical immunotherapy is undergoing a renaissance, with
recent rapid-fire US Food and Drug Association (FDA) ap-
proval of numerous immunotherapies across several tumor
types, including ipilimumab, pembrolizumab and nivolu-
mab for metastatic melanoma, nivolumab for non-small
cell squamous cell lung cancer, sipuleucel-T for prostate
cancer, and blinatumomab for acute lymphocytic leukemia
(ALL). In parallel, advances in research tools for basic and
translational investigation have afforded an enhanced un-
derstanding of the fundamentals of tumor immunology,
laying the foundation for subsequent development of the
next generation of immunotherapeutic approaches. These
approaches include therapeutic antibodies against novel* Correspondence: paged@mskcc.org
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fic antibody constructs, and combination therapies. In
November 2014, the Society for Immunotherapy of
Cancer (SITC) held the second annual Primer on Tumor
Immunology and Cancer Immunotherapy, organized by
Drs. Willem W. Overwijk and Padmanee Sharma. In this
review, we will summarize the key topics presented by the
faculty, focusing upon recent advances in the field of im-
munotherapy. This year’s faculty included Dr. Vincenzo
Bronte, MD (innate immunity), Dr. Lisa H. Butterfield,
PhD (dendritic cells), Dr. Jonathan Powell, MD/PhD
(adaptive immunity), Dr. Carl H. June, MD (adoptive
T-cell therapy), Dr. Sattva S. Neelapu, MD (anti-tumor
antibodies), Dr. Margaret K. Callahan, MD/PhD (obstacles
to driving an immune response), Dr. Willem W. Overwijk,
PhD (cancer vaccines), Dr. James P. Allison, PhD (target-
ing immune checkpoints in cancer therapy), Dr. Sasha
Gnjatic, PhD (immune monitoring), and Dr. Padmanee
Sharma, MD/PhD (pre-surgical clinical trial design).cle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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Page et al. Journal for ImmunoTherapy of Cancer  (2015) 3:25 Page 2 of 10Innate immunity
The innate immune system is evolutionarily conserved
across both vertebrates and non-vertebrates, and provides
a rapid, but non-specific, protective immune response to
invading pathogens, The innate immune system responds
within minutes and does not generate memory, but not-
ably can stimulate and shape long-lasting antigen-specific
immunity through a variety of mechanisms. Principal
components of innate immunity include epithelial bar-
riers (skin and mucosal membranes), pattern recognition
receptors (PRRs), effector cells (monocytes/macrophages,
natural killer (NK) cells, dendritic cells (DCs), mast cells,
neutrophils, innate lymphoid cells, and eosinophils among
others) and humoral components (complement proteins
and collectins).
The innate immune response can be initiated through
activation of PRRs such as Toll-like receptors (TLR).
These receptors can be extracellular, cytosolic, or endo-
somal. Pathogen associated molecular patterns (PAMP)
are molecules shared by groups of pathogens (i.e. gram
positive and gram negative bacteria), are not present in
mammalian cells, and are capable of binding PRRs. These
include bacterial cell wall structures such as lipopolysac-
charide, as well as nucleic acids such as double-stranded
RNA. Similarly, damage associated molecular patterns
(DAMPs) such as HMGB1, DNA, RNA and S100 mole-
cules can activate PRRs. Activation of PRRs leads to inflam-
matory cytokine release, which ultimately contributes to
maturation of dendritic cells and presentation of antigens
to the adaptive immune system. In tumors, anti-neoplastic
therapies may promote tumor apoptosis, inflammation, and
presentation of tumor-associated antigens with activation
of anti-tumor T cell immunity. In contrast, persistent hyp-
oxia in growing tumors leads to necrosis and chronic
release of HMGB1, promoting angiogenesis and tumor
growth through the recruitment of suppressive tumor-
associated macrophages and endothelial precursor cells [1].
The innate immune response is driven by a number of
cell types and mediated by cytokines including tumor ne-
crosis factor (TNF), interleukin-1 (IL-1), IL-12 and inter-
feron gamma (IFN-γ), among others. Macrophages have
been classically implicated in microbicidal actions including
phagocytosis and bacterial/fungal killing, as well as antigen
presentation to T cells. However, macrophages may have
positive or negative effects in the tumor microenviron-
ment. In this regard, the distinction between classically ac-
tivated M1 macrophages and alternatively activated M2
macrophages is an important one. Whereas M1 macro-
phages are responsible for phagocytosis and tumouricidal
activity, M2 macrophages generate anti-inflammatory cy-
tokines and play a role in wound repair and fibrosis, and
may promote tumor survival, for example by promoting
tumor vascularization and immune suppression [2,3]. NK
cells also play an important role in innate immunity, asthey are capable of killing injured cells, infected cells, and
phagocytosed microbes. NK cells are activated by receptors
which recognize stress-induced molecules on the cell surface,
both in the setting of infection or neoplasm. NK cells also
express inhibitory receptors which bind class I major histo-
compatibility complex (MHCI), and exhibit cytotoxic activity
against tumors that aberrantly downregulate MHCI. Lastly,
innate lymphoid cells (ILC) are crucial for regional immun-
ity. They were first described for their role in the develop-
ment of lymphoid tissues and generating inflammation at
barrier surfaces after infection or tissue damage. More re-
cently, however, a role in the transition from innate to adap-
tive immunity, and in chronic inflammation, has been
elucidated [4]. Along these lines, recent advances suggest
that components of the intestinal microbiota can alter gut
homeostasis and promote chronic inflammation, thereby
leading to intestinal tumor development [5].
Humoral mechanisms of innate immunity include comple-
ment proteins, cytokines, and other plasma proteins such as
collectins, ficolins and pentraxins. The complement system is
a branch of the immune system which, through a biochemical
cascade involving multiple proteins, clears pathogens through
cell lysis and phagocytosis. Complement is likely to have a
dual role in cancer, as on the one hand it contributes to pro-
tection through direct complement activation or as part of
complement-dependent cytotoxicity of tumor-directed thera-
peutic antibodies. Alternately, the generation of C5a in the
tumor microenvironment can attract myeloid-derived sup-
pressor cells (MDSCs) and induce the generation of reactive
oxygen and nitrogen species through the C5a receptor, which
impairs the tumor-directed effect of T cells [6]. There is evi-
dence that both acute and chronic inflammation may promote
genetic abnormalities and cancer progression, suggesting that
modulation of the innate immune system has the potential to
impact our approach to cancer immunotherapy.
Dendritic Cells
DCs lie at the interface of innate and adaptive immune re-
sponses. First described by Steinman and Cohn in 1973, DCs
can develop from either myeloid of lymphoid hematopoietic
lineages, giving rise to a multitude of subtypes each with
unique function. Adding to the diversity of subtypes is the
localization of the particular DC types within different tissues
in the body, as the milieu is critical for defining the ultimate
function of the DC and their capacity to facilitate an anti-
tumor immune response [7].
DCs start off in an immature state, acting as sentinels
in their respective tissues. At this stage of maturation,
DCs are very phagocytic, constantly sampling their en-
vironment through pinocytosis, micropinocytosis, and
receptor-mediated uptake. Innate receptors, including
TLRs and scavenging receptors, can facilitate maturation
and activation of these DCs, and direct the nature of the
immune response they trigger. For example, ligation of
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DCs leads to secretion of interferon alpha (IFNα) and an anti-
tumor T-helper type 1 (TH1) response. Similarly, ligation of
TLR3, TLR4, TLR5, TLR8 and TLR11 on human myeloid
DCs leads to aTH1 response, with the secretion of the hetero-
dimeric IL-12p70. On the other hand, ligation of TLR1,TLR2
or TLR6 in these human myeloid DCs leads to a tolerogenic
T-helper type II (TH2) response, with low IL-12p70 and high
IL-10 secretion [8]. In the absence ofmaturation or inflamma-
tory signals, antigen uptake and presentation results in a regu-
latory and tolerant response. On the other hand, antigen
uptake that occurs in the presence of DAMPs/PAMPs leads
to DCmaturation and a decrease in phagocytic ability. These
mature DCs traffic from the periphery to the lymph nodes,
where they present the antigen to T-cells within the lymph
node. In the right immunogenic setting, DCs increase their
cell-surface expression of MHCI, major histocompatibility
complex class II (MHCII), CD80, CD86, and secrete a number
of immunogenic cytokines and chemokines, which in turn
may activate T-cells and promote an anti-tumor TH1
response.
Given the ability of DCs to skew immune responses,
there has been keen interest in these cells for the devel-
opment of immunogenic antitumoral therapies. In 2010,
the FDA approved a DC-based immunotherapy (sipuleu-
cel-T) for men with metastatic castrate resistant prostate
cancer. This cell-based vaccine uses ex-vivo pulsed au-
tologous peripheral blood monocytes, incubated with a
fusion protein that links Prostatic Acid Phosphatase (the
target antigen) to GM-CSF (a factor that serves to ma-
ture monocytes towards DCs). In a randomized con-
trolled trial in men with castrate resistant prostate
cancer, sipuleucel-T improved survival by a median of
4.1 months compared to placebo (p = 0.03). This im-
munotherapy was also well tolerated and safe, with the
main side effects limited to chills, fever, and headache
[9].
Overall, DC-based therapies have led to suboptimal clin-
ical responses, and to date, sipuleucel-T remains the only
FDA approved DC-based immunotherapy. However, many
unanswered questions remain when it comes to our funda-
mental understanding of this approach. For example, in
the trials utilizing ex vivo expanded autologous DCs, (1)
what DC subtype is the most potent, (2) what are the opti-
mal culture and maturation conditions, (3) what is the best
way to load tumor antigen, (4) what is the ideal dose, and
route of administration? In contrast to ex vivo expanded
autologous DCs, in vivo targeting of tumor antigens teth-
ered to antibodies recognizing DC-specific receptors is an-
other strategy being investigated.
Adaptive immunity
Two groups of immune cells, B-cells and T-cells, work
in concert to generate the adaptive immune response,which is characterized by three distinct features: diver-
sity, specificity and memory. T-cells and B-cells each are
capable of recognizing a diverse repertoire of specific an-
tigens, but accomplish this in different ways [10]. T-cells,
by means of the T-cell receptor (TCR), recognize peptide
fragments (epitopes) presented on the surface of cells in
the context of MHCI/MHCII surface receptors. B-cells
recognize antigen through either B-cell receptor (BCR),
or a soluble, secreted component of the BCR called an
“antibody,” which may directly bind antigens found in
serum [11].
Unlike most other receptors in the body, the DNA se-
quences of the TCR and BCR are not merely encoded by
an individual’s germline DNA. Rather, the diversity and
specificity of unique receptors are generated by a som-
atic recombination process. During this recombination
process, Variable, Diversity, and Joining (VDJ) gene seg-
ments are randomly recombined, creating the genetic di-
versity of the TCR and BCR sequences. Following this
recombination process, the estimated number of TCRs
and BCRs that can be generated in an individual is of the
order of approximately 2.5 × 10 [7]. Thus, the recombin-
ation of genes generates the underlying diversity of TCRs
and BCRs, which then enables a diverse immune response
against a broad repertoire of potential antigens [11].
These diverse cells, each with their own unique TCR or
BCR, are present in the immune milieu, constantly sur-
veying for the presence of their target “cognate” antigen.
When a T-cell or B-cell binds to its cognate antigen under
the right conditions, it will proliferate to create a clonal
population, thus allowing for the generation of a potent,
antigen-specific effector response. In addition to generat-
ing this effector population, cells with enhanced longevity
are generated which provide “immunologic memory” and
protection if the antigen is encountered again later.
B-cells generate what is termed a ‘humoral response.’
B-cells initially harbor BCRs on their surface, and are
triggered to proliferate when they encounter a specific
antigen. This process leads to the generation of plasma
cells that generate large quantities of antibody, which are
soluble BCRs that are released from the surface of plasma
cells into the circulation. Antibodies have a basic Y-shaped
structure, consisting of 2 heavy chains in the middle,
flanked by two smaller light chains on the outside. The
fork end of this structure forms the antigen binding site or
“Fab” (fragment of antigen-binding) region. The other end
of the antibody molecule consists of the two heavy chain
regions alone, called the “Fc” region (constant fragment).
The constant region defines the subtype or “isotype” of
antibody, each with a distinct function. IgA antibodies are
involved in the defense of mucosal surfaces. IgD anti-
bodies are found mainly on naïve B-cells before they en-
counter antigen. IgE antibodies are generated in response
to parasitic infections and allergic responses. IgG antibodies
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the past, and account for post-vaccination antibody re-
sponses. Finally, IgM antibodies are a pentamer and are
generated acutely during infection, preceding IgG. Anti-
bodies may bring about their effect against pathogens
through a number of different mechanisms, including
neutralization (direct binding to pathogen), opsonization
(binding of pathogen to facilitate phagocytosis), precipita-
tion (binding pathogens into a formation), and comple-
ment activation [10].
T-cells are divided into several subtypes, defined by their
function and expression of surface proteins. Cytotoxic
T-cells express CD8, and upon activation can proliferate
and directly kill infected or cancerous cells. Activation of
cytotoxic T-cells requires the presence of two signals: the
first signal (signal 1) consists of recognition of foreign
antigen in the context of TCR and MHCI molecules,
which are present on all human cells. Signal 2 is generated
by a variety of co-stimulatory (for example CD28) and co-
inhibitory molecules (for example cytotoxic T-lymphocyte
antigen 4, CTLA4) that bind to ligand on target cells. An
abundance of co-inhibitory signals may lead to a “tolero-
genic” state by which cytotoxic T-cells lose their cytotoxic
effector function, whereas co-stimulatory signals may pro-
mote cytotoxic effector function [12].
Helper T-cells express CD4 and facilitate a coordinated
immune response involving cytotoxic T-cells, B-cells, and
the innate immune arm. When naïve (antigen-inexperi-
enced) CD4+ T-cells are stimulated with antigen in the
context of MHCII molecules (found on antigen presenting
cells such as B-cells, macrophages, and dendritic cells),
the helper cell may differentiate into a TH1, TH2, T-helper
type 17 (TH17), or regulatory (Treg) T-cell based upon the
cytokine milieu [13]. TH1 cells secrete IFNγ and support
antiviral and antitumor responses. TH2 cells secrete IL-4
and IL-13, support antiparasitic responses, and may ham-
per the anti-tumor response. The role of TH17 cells and
other subtypes are being elucidated. Finally, Tregs inhibit
and dampen an immune response, and have been attrib-
uted to tumor immune escape [13].
Adoptive therapy
Adoptive cellular therapy is a field that involves ex vivo
manipulation of autologous T cells and re-infusion in order
to generate a robust anti-tumor response. Manipulation of
T cells consists of either gene insertion of a chimeric anti-
gen receptor (CAR) or engineered TCR, or the expansion
of endogenous tumor infiltrating lymphocytes (TILs).
The primary components of a CAR are 1) an extracellular
single-chain variable fragment (the “antigen-specific” side
of an antibody) targeting a tumor antigen such as CD19 on
lymphocytic leukemias; 2) a transmembrane linker domain;
and 3) an intracellular CD3z (intracellular) domain, confer-
ring downstream TCR signaling upon binding to tumorantigen. CAR-engineered T-cells are capable of binding
tumor and being directly activated without the need for
antigen-binding via the traditional TCR:MHC complex.
Second-generation CARs have been enhanced by the
addition of a co-stimulatory domain such as CD28 or 4-
1BB. CAR-engineered T-cells are potent, however they
may have short in vivo persistence.
The first published clinical example of CAR T-cell ther-
apy in humans was a study of anti-CD19 CAR T-cells for
the treatment of chronic lymphocytic leukemia (CLL),
whereby 2 of 3 treated patients had durable remissions
[14]. This study showed that CD19-directed CAR T-cells
are capable of killing >1000 tumor cells per infused T-cell,
and in at least some cases, there was long-term detection
of CAR T-cells in blood by PCR, which correlated with
durability of remission [15]. Subsequent enrollment on
the CLL trial, however, proved that most patients did not
experience dramatic long term remissions. This is in con-
trast to ALL, whereby infused anti-CD19 CAR T-cells
demonstrated robust efficacy. The University of Pennsyl-
vania trial of primarily pediatric ALL demonstrated a 90 %
complete remission rate with a 6-month overall survival
of 78 % [16].
TCR gene transfer has also been attempted as an alter-
native to CAR T-cell therapy. Endogenous TCRs specific
to tumor-associated antigens are oftentimes low affinity
and may not generate sufficient signal to mount a suc-
cessful anti-tumor immune response. With gene transfer
technologies, high-affinity TCR genes can be transferred
to autologous T-cells, which then have the capacity to
impart viral-like (strong) affinity against tumor-specific
peptide:MHC complexes. In the clinic, this technique has
been less successful than CAR therapy. In a study of TCR
gene transfer against the cancer-testis antigen MAGE-A3,
two patients died of cardiogenic shock. Autopsy studies
demonstrated that the adoptive T-cells cross-reacted to a
cardiomyocyte protein (titan), leading to death of cardiac
myocytes. Similarly, in another study of anti-MAGE-A3
T-cells in 9 patients with various solid malignancies, 5 of 9
patients experienced objective response, however 3 pa-
tients developed severe neurologic adverse events, resulting
in 2 treatment-related deaths. Brain biopsies demonstrated
possible MAGE protein expression in the brain, once again
highlighting the challenge of achieving tumor specificity
with engineered TCRs [17–19].
Ex vivo expansion and re-infusion of TILs are the third
type of adoptive T cell therapy. Great advances have re-
cently been made in the culture process to allow for the less
laborious and more rapid expansion of clinically relevant
quantities of TILs. In Europe there is a phase III trial of
TILs for melanoma with the hopes to generate robust effi-
cacy data and gain approval of TILs as a standard therapy.
After many years, adoptive cellular therapy may be
headed towards FDA approval based on the early stage
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and non-Hodgkin lymphoma. Gene transfer of TCRs
may also be headed towards later stage trials for sarcoma
and melanoma. Future questions in the field include
how to combine adoptive T cell therapy with other types
of immunotherapy, how to scale up and streamline
manufacturing, and the challenge of identifying novel
targets with minimal “on target, off tumor” toxicity.
Anti-tumor antibodies
Monoclonal antibodies (mAb) have been employed in a
diversity of roles for the treatment of cancer. The “magic
bullet concept” initially postulated the use of antibodies
to target tumors [20]. Technical advances including the
development of hybridoma technology and genetic ap-
proaches allowing the construction of “humanized” or
fully human antibodies have facilitated the development
of antibodies for use in the clinic.
The basic antibody structure consists of two heavy
chains and two light chains, each of which has a variable
portion and a constant region. The variable region of the
heavy and light regions forms the antigen biding sites
(Fab); each antibody has two Fab sites. The complemen-
tarity determining region (CDR) is within the antigen
binding site and is critical for conferring specificity to the
antibody. For example, rituximab and ofatumamab are both
therapeutic mAb that target different sites of CD20 as they
have different CDR regions [21]. Additionally, the class or
subclass of the immunoglobulin can impact its function.
Most antibodies developed for the clinic are in the IgG
class, which is subdivided into IgG1, IgG2, IgG3, and IgG4
subclasses. IgG1 mAb subtypes typically have the most
significant antibody-dependent cell-mediated cytotoxicity
(ADCC, i.e. binding and killing of antibody-bound targets
via NK cells and other effector cells), whereas mAbs of the
human IgG4 subtype are thought typically have minimal
ADCC, which may be consideration in the development
of antibodies for clinical application.
Monoclonal antibodies for clinical use are classified and
named based on the percentage of the murine component:
murine (−omab), chimeric (−ximab), humanized (−zumab),
and human (−umab). Human mAb are produced by using
a phage antibody library, transgenic mice, or immortalized
human memory B cells. Humanized and fully human mAb
are preferred as they are less immunogenic.
Monoclonal antibodies act on their targets in an Fc
dependent or an Fc independent fashion. Fc dependent
mechanisms of action are as follows: ADCC, antibody-
dependent cellular phagocytosis (ADCP), and comple-
ment dependent cytotoxicity (CDC). On the other hand,
direct apoptosis, agonistic and antagonistic mediated in-
teractions are Fc independent. Various strategies have
been employed to enhance the efficacy of mAb such as
glyco-engineering of the Fc portion in order to enhanceADCC, for instance obinutuzumab (GA101) as compared to
rituximab [22]. Additionally, therapeutic antibodies can be
enhanced by conjugating them to radioisotopes, cytotoxic
molecules, or cytokines, thereby improving the likelihood
of cell kill. One example of an antibody-drug conjugate
(ADC) is trastuzumab emtansine (T-DM1), which is an
antibody targeting anti-human epidermal growth factor
receptor 2 (HER2), conjugated to the cytotoxic molecule,
DM1. T-DM1 improves survival and is FDA-approved for
HER2-overexpressing metastatic breast cancer, and is be-
ing additionally evaluated in both early stage breast cancer
and HER2-overexpressing gastric cancer [23].
In addition to conjugating antibodies to cytotoxic agents,
bispecific antibodies have been developed which link the
variable regions of two antibodies together, thereby creating
a construct specific to two antigens. The FDA-approved
drug, blinatumomab, is specific to both CD3 and CD19,
and functions to engage T-cells with malignant CD19-
positive leukemia clones, directly leading to T-cell activa-
tion and cytolysis of the adjacent leukemia cell [24].
Obstacles to immunotherapy
The concept of immune surveillance was described in
the 1950s by L. Thomas and M. Burnet. They theorized
that T cells played a pivotal sentinel role in the immune
system’s response against cancer, potentially recognizing
and eliminating cancerous cells. Later, Schreiber and col-
leagues proposed a hypothesis called the three E’s of can-
cer immunoediting: Elimination, Equilibrium, and Escape
[25]. These three E’s illustrate how, with selective immune
pressure, cancers can be sculpted over time to become
progressively resistant to the immune response. During
the elimination phase, adaptive and innate immune arms
work in tandem to recognize and destroy tumors. However,
during the equilibrium phase, immune pressure results in
the acquisition of resistance mechanisms by tumors that
allow for survival of cancer in a steady state. Finally, over
time, during the escape phase, tumor variants may emerge
that are no longer recognized by adaptive or innate im-
mune arms, allowing for outgrowth of tumors and clinical
manifestation of cancer.
The methods by which tumors evade immune elimination
are an active area of research. These can be categorized into
tumor-intrinsic and tumor-extrinsic. Tumor-intrinsic mech-
anisms can include antigen loss, MHC loss, secretion of
immunosuppressive cytokines or expression of cell-surface
markers such as programmed death ligand 1 (PD-L1) that
may alter T cell function. Tumor-extrinsic factors involve
geographic barriers as well as a range of suppressive or
regulatory immune cells including regulatory T cells and a
heterogenous population of MDSCs and alternative acti-
vated M2-like tumor-associated macrophages (TAMs).
Tregs are characterized by expression of the transcription
factor FOXP3 and are critical for the prevention of
Page et al. Journal for ImmunoTherapy of Cancer  (2015) 3:25 Page 6 of 10autoimmunity and the maintenance of immune homeo-
stasis. Tregs modulate the immune response by a variety of
mechanisms. Potential opportunities for targeting Tregs in-
clude Treg depletion via blocking antibodies or anti-CD25
immunotoxin, modification of trafficking or exploitation
of T-cell plasticity [26]. Recent data suggests that CTLA-4
blocking antibodies such as ipilimumab may act, in part,
via their role in depleting Tregs from the tumor micro-
environment [27].
MDSCs are a population of immune derived cells that
inhibit T cell and dendritic cell function via a variety of
mechanisms [28]. These cells may play an important roll
in immune editing in metastatic cancer. For example,
metastatic melanoma patients have been observed to
have increased quantities of MDSCs [29]. These CD14+
MDSC were also shown to directly suppress T-cell pro-
liferation ex-vivo. In addition, MDSC are associated with
poorer survival outcomes after ipilimumab. TAMs are
monocytes that are recruited to the tumor microenviron-
ment. Cytokines secreted by the tumor can polarize re-
cruited monocytes to either resemble M1 macrophages
which have tumoricidal activity or, more commonly, to re-
semble M2 macrophages. These M2-like TAMs can shape
the tumor microenvironment by secreting a variety of cyto-
kines for tissue remodeling, enhanced invasion and metas-
tasis and increase immune suppression (mostly via IL-10
production) [30]. There are a number of compounds that
are being explored to target MDSCs and TAMs, for
example colony-stimulating factor 1 receptor (CSF-1R)
blocking agents that are currently under development,
however, specificity for these agents remains a significant
challenge.
Lastly, one of the now well-known regulatory mecha-
nisms which serve to dampen or shut down T-cell re-
sponses are immune checkpoint molecules expressed on
the T-cell surface, including CTLA-4 and programmed
death 1 (PD-1). Two anti-PD-1 antibodies, pembrolizumab
and nivolumab, and one anti-CTLA4 antibody, ipilimu-
mab, are FDA approved for the treatment of metastatic
melanoma. There continues to be active investigation into
new blocking antibodies of inhibitory receptors such as
lymphocyte activation gene 3 (LAG-3).
Cancer vaccines
Much like vaccines for the prevention of infectious dis-
ease, vaccines for cancer are designed to induce an adap-
tive immune response to an administered antigen. A key
difference, however, is that cancer vaccines have generally
been studied as therapeutic, rather than prophylactic,
agents. In addition, unlike pathogens, for which non-self
antigens may be relatively easily identified and defined,
the identification of appropriate antigen targets to gener-
ate an effective anti-tumor response is more challenging.
Tumor antigens may be categorized as tumor associateantigens (TAA) which are present in tumor cells, but may
also be present in some normal cells. An example of a
TAA would be MAGE, found in many melanomas, but
also present in the testis. Alternatively, tumor antigens
may be categorized as tumor specific antigens (TSA), anti-
gens that are completely unique to the tumor and not
found in normal tissue. Antigens generated by random
mutations in the tumor cells would be an example of
TSAs. The quantity and quality of TSA and TAA antigens
varies widely among cancers.
While cancer vaccines have been investigated for de-
cades, the first approved treatment for human cancer based
on the principle of vaccination is sipuleucel T (FDA-ap-
proved in 2010). This approach, which is now an accepted
therapy for patients with advanced prostate cancer, begins
with the harvesting of a patient’s antigen presenting cells,
which are then exposed to tumor antigen ex vivo, and sub-
sequently returned to the patient. Despite the experience
with sipuleucel-T, the more conventional approach of ad-
ministering an antigen into the patient in order to trigger a
productive adaptive immune response is ongoing. A critical
component of such vaccination is the so-called “adjuvant”,
a second agent that is co-administered to enhance the re-
sponse to the antigen. There are multiple types of adju-
vants, including those designed to prolong antigen release,
to protect the antigen from degradation, to increase antigen
uptake by antigen presenting cells, or to induce an inflam-
matory microenvironment.
Despite much research and clinical activity in this area,
so far most cancer patients do not achieve tumor regres-
sion with vaccination, even when tumor-specific T-cells
are induced. Some possible explanations for this are that
1) too few antigen-specific T-cells develop; 2) the selec-
tion of which antigens to target is sub-optimal; 3) the
vaccine induced T cells have sub-optimal anti-tumor ac-
tivity 4) T-cells are being suppressed by tumor-derived
immunosuppressive signals; 5) or activated T-cells are
prevented from entering the tumor [31]. Fascinatingly, it
has also been demonstrated that vaccines may blunt
their own activity by diverting antigen-specific T-cells
away from tumors to sites of vaccination where they
undergo apoptosis. Fortunately, this obstacle may be
overcome by using dissipating vaccine formulations [32].
A history of extensive experience with cancer vaccines,
and the advent of immune checkpoint inhibitors with po-
tent anti-tumor activity, has raised hopes of successfully
combining vaccination with other immunotherapies.
While not all such combinations are likely to be effective,
there are many studies showing that this strategy can in-
deed boost vaccine potency.
Immune checkpoint antibodies
Immune checkpoint modulation has transformed the treat-
ment of cancer, with the FDA-approval of the CTLA-4
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bodies nivolumab and pembrolizumab. CTLA4, the proto-
typical co-inhibitory checkpoint receptor, attenuates the
T-cell response by inducing inhibitory downstream signal-
ing and competitively binding with the B7 ligand on anti-
gen presenting cells [33]. Blockade of CTLA4 improves
survival in both mice [34] and in humans: in a phase III
trial, melanoma patients with previously treated, advanced
melanoma received ipilimumab 3 mg/kg with or without
glycoprotein (gp) 100 peptide vaccine vs gp100 peptide
vaccine alone [35]. Median overall survival (OS) in the
ipilimumab and ipilimumab + gp100 cohorts was 10.1 and
10.0 months, respectively, versus 6.4 months for the gp100
control arm (p < .001). Following ipilimumab, survival ap-
pears to be durable, as indicated by a plateau in the sur-
vival curve beginning around year 3 (21 % 3-year survival)
and persisting for >10 years [36]. Immune-related toxicities
such as colitis, hepatitis, pneumonitis, or hypophysitis may
be serious, but can be mitigated with careful monitoring
of symptoms and algorithm-guided early intervention, for
example with corticosteroids [37].
PD-1 is another immune inhibitory receptor expressed
on T-cells with therapeutic potential [38]. The anti-PD-1
antibodies nivolumab and pembrolizumab have activity
in patients with both ipilimumab-naïve and ipilimumab-
treated advanced melanoma and have been recently FDA ap-
proved in the latter patient population [39,40]. In addition,
PD-1 or PD-L1 blocking antibodies have demonstrated ac-
tivity in a wide variety of additional tumor types including
non-small cell lung cancer (NSCLC), renal cell cancer,
bladder cancer, and Hodgkin’s lymphoma among others.
Nivolumab has recently been approved by the FDA for
the treatment of NSCLC of squamous histology based
upon the results of a Phase 3 study showing a benefit in
overall survival of 3.2 months for patients who received
nivolumab (clinical trial NCT01642004).
The combination blockade of CTLA4 and PD-1 path-
ways may be more efficacious in promoting antitumor
immunity than either agent alone [41]. In a phase I study
of simultaneous administration of nivolumab and ipili-
mumab in patients with advanced melanoma, dramatic
tumor reduction (>80 % tumor volume) was observed in
42 % of the initial 53 patients with advanced melanoma,
with a 2-year survival rate of 88 % in the optimal dosing
cohort of nivolumab, 1 mg/kg, and ipilimumab, 3 mg/kg
[42,43]. These checkpoint inhibitors are also being eval-
uated in a variety of tumor types including lung cancers,
urologic malignancies, hematological malignancies.
Monitoring T-cell and B-cell responses to immunotherapy
Laboratory assays may be used to monitor B-cell and
T-cell function in response to immunotherapy, and may
one day serve as biomarkers to inform clinical decision-
making. The traditional method of monitoring B-cellfunction is by measuring serum antibody reactivity by
enzyme linked immunosorbent assay (ELISA). By this
method, antibody production against cancer-associated
antigens have been detected and monitored in cancer pa-
tients. For example, sero-reactivity against NY-ESO-1, a
cancer-testis antigen expressed by some melanomas—has
been associated with clinical benefit following anti-
CTLA4 therapy [44]. One limitation of ELISA, however, is
that a priori knowledge of the antigenic target is neces-
sary. Alternatively, next generation protein microarrays
provide the opportunity to simultaneously measure sero-
reactivity against thousands of antigens, allowing for possible
antigen discovery. These microarrays have high concord-
ance with ELSA, and have been used to identify antigenic
targets and sero-reactivity patterns in ovarian cancer, pan-
creatic cancer, and other cancers [45]. Alternatively, an
emerging method to monitor B-cell function is to enu-
merate ectopic tumor-associated lymphoid structures
(TLS) found within tumors. TLS contain the hallmark
components of the lymphoid follicle (i.e. naïve B-cells, ger-
minal center B-cells, and somatic hypermutation/class
switch machinery), have been associated with favorable
prognosis, and contain B-cells that secrete auto-antibodies
against known tumor-associated antigens such as NY-
ESO-1 [46,47].
Multiple methods have been developed to monitor T-cell
function, for example polychromatic flow cytometry to
quantify the degree of peripheral blood T-cell activation as
measured by expression of ICOS [48]. However, assess-
ment of TILs may be additionally informative. Quanti-
fication of CD3 (T-cells), CD8 (cytotoxic T-cells) and
CD45RO (memory T-cells) by immunohistochemistry is
highly prognostic of recurrence across multiple tumor
types [49]. For example, early stage colorectal tumors with
dense CD8+ and CD45RO+ infiltrates have dramatically
lower recurrence (4.8 % 5-years recurrence) compared to
tumors with low infiltrates (75 % 5-years recurrence) [50].
These parameters have formed the basis of the proposed
“immunoscore,” which if validated may inform the clinical
decision to treat a patient with adjuvant therapy. More so-
phisticated analytic tools of TILs are being developed and
may provide additional prognostic information or en-
hanced understanding of the interplay of various immune
subsets. For example, RNA transcriptome analysis has
been used to characterize the transcriptional profiles of
various immune cellular subsets. By RNA-seq, TH17 tran-
scriptional profiles were associated with adverse prognosis
in colorectal cancer. Furthermore, tumors of different T-
stages each exhibited a distinct immunologic transcrip-
tional profile, suggesting temporal evolution of interplay
between the tumor and immune system [51].
Conventional immune monitoring platforms measure
only the average signal across all the cells within a sam-
ple. However, next-generation techniques may allow for
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flow cytometry techniques allow for sorting and classi-
fication of cells by upwards of 20 different parame-
ters. Alternatively, mass cytometry utilizes antibody stains
conjugated to rare-earth metal isotopes that emit non-
overlapping signals, thus increasing the theoretical limit of
characterization to upwards of 100 distant parameters
[52]. Finally, “microfluidics” platforms and other technolo-
gies are being developed to isolate and perform whole
genome and RNA sequencing on individual cells. These
tools, while in their infancy, will provide a wealth of mech-
anistic information, and may one day be used to predict
response to immunotherapy and guide clinical decision-
making [53].
Immunotherapy clinical trial design
The rapid expansion of the immuno-oncology field has
likewise led to the identification of an ever-expanding list
of critical issues that require further investigation, such as
identification of the molecular mechanisms of antitumor
efficacy and off-target toxicity, identification of predictive/
prognostic biomarkers, and the identification of novel
therapeutic targets. One approach to investigating these
unanswered questions is designing immunotherapy trials
that integrate surgical resection or tissue sampling during
the course of treatment. This allows for an iterative
process of hypothesis generation from patient samples
that can be then tested in a more tightly controlled labora-
tory setting and lead to novel future trials.
An illustrative example of this approach is the series of
studies that identified ICOS as a pharmacodynamic
marker of CTLA4 inhibition [48] and a potential thera-
peutic target [54]. Initially, twelve patients with bladder
cancer were treated with 2 cycles of ipilimumab in the
neoadjuvant setting [55]. Increased levels of ICOS expres-
sion on CD4+ cells (CD4 + ICOShi) in both tumor tissue
and plasma were seen, and sustained increases of circulat-
ing CD4 + ICOShi T cells were associated with clinical
benefit [55]. Increased frequency of CD4+ICOShi T cells
was 71% sensitive and 96% specific as a pharmacody-
namic biomarker of anti-CTLA4 treatment across
cancer subtypes in this small initial cohort [48], but
larger studies in over 200 patients have demonstrated
ICOS+ CD4 T cells to have sensitivity of 91% and speci-
ficity of 96% as a pharmacodynamic biomarker of anti-
CTLA-4 therapy (unpublished data, PS).
Mouse models were then engineered that suggested
ICOS is necessary for optimal anti-tumor efficacy of
CTLA4 treatment [56]. ICOS signals through the PI3K
pathway to increase Tbet expression, which underlies
the development of TH1 cells that lead to anti-tumor
responses [57]. Ongoing preclinical work with an ICOS-
ligand expressing vaccine in murine models shows im-
provements in anti-tumor responses to CTLA4 inhibition[54]. Together, these data suggest that one strategy to im-
prove clinical outcomes with CTLA4 blockade may be to
increase ICOS expression and signaling.
As the development of ICOS shows, varied clinical
trial designs can be used to investigate biomarkers and
mechanisms of tumor response or resistance that will
lead to the next phase of clinical trial design. As the field of
immuno-oncology continues to expand, these biomarker-
driven studies will serve as invaluable tools for discovery
and design of new therapies.
Conclusion
As foreshadowed by the work of Drs. William B. Coley
and Lloyd J. Old, advances in our understanding of the
innate and adaptive immune response have finally trans-
lated into remarkable gains in clinical benefit for pa-
tients across of variety of malignancies. These gains are
occurring across several classes of immunotherapy: for
example, the FDA has approved therapeutic immune
checkpoint antibodies for metastatic melanoma and lung
cancer, cellular vaccines for prostate cancer, and bispeci-
fic antibodies for leukemia. Additional therapies such as
CAR-engineered T-cells for leukemia are likely soon to fol-
low. Looking forward, clinical advances are likely to accel-
erate as a result of broadening our application of these
therapeutic strategies to different tumor targets (for ex-
ample employing CAR-engineered T-cells for solid tumors,
or checkpoint antibodies for leukemias), or combinatorial
immunotherapy approaches (for example enhancing CAR-
engineered T-cells by co-administering immune check-
point antibodies). Future challenges will be to understand
the optimal sequencing of numerous effective immune
therapies and alternative treatment approaches, improving
access to immune therapy, and developing bioinformatics
approaches to translate next-generation immune monitor-
ing data into clinical use [58,59].Abbreviations
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